Soldierer M, Bister A, Haist C, Thivakaran A, Cengiz S, Sendker S, et al. Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies. Front Immunol. 2022;13:847008 pubmed publisher

Kräter M, Abuhattum S, Soteriou D, Jacobi A, Krüger T, Guck J, et al. AIDeveloper: Deep Learning Image Classification in Life Science and Beyond. Adv Sci (Weinh). 2021;8:e2003743 pubmed publisher

Wullenkord R, Reicherts C, Mikesch J, Marx J, Wethmar K, Albring J, et al. Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia. Ann Hematol. 2021;100:587-589 pubmed publisher

Nehama D, Di Ianni N, Musio S, Du H, Patanè M, Pollo B, et al. B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres. EBioMedicine. 2019;47:33-43 pubmed publisher

Li C, Psatha N, Gil S, Wang H, Papayannopoulou T, Lieber A. HDAd5/35++ Adenovirus Vector Expressing Anti-CRISPR Peptides Decreases CRISPR/Cas9 Toxicity in Human Hematopoietic Stem Cells. Mol Ther Methods Clin Dev. 2018;9:390-401 pubmed publisher

Fazekas B, Moreno Olivera A, Kelly Y, O HARA P, Murray S, Kennedy A, et al. Alterations in circulating lymphoid cell populations in systemic small vessel vasculitis are non-specific manifestations of renal injury. Clin Exp Immunol. 2018;191:180-188 pubmed publisher

Birnbaum M, Berry R, Hsiao Y, Chen Z, Shingu Vazquez M, Yu X, et al. Molecular architecture of the αβ T cell receptor-CD3 complex. Proc Natl Acad Sci U S A. 2014;111:17576-81 pubmed publisher

D Acquisto F, Crompton T. CD3+CD4-CD8- (double negative) T cells: saviours or villains of the immune response?. Biochem Pharmacol. 2011;82:333-40 pubmed publisher